Option chain shows key data for Monogram Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Monogram Technologies.

Monogram Technologies (NASDAQ:MGRM) Stock, Option Chain

Monogram Technologies

Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Screenshot 2024-08-28 at 9.51.40 PM

Biotech

General

MGRM

Monogram Orthopedics (NASDAQ: MGRM) Readies Commercialization Of Next-Gen Surgical Robot

Screenshot 2024-08-27 at 7.59.58 PM

Monogram Orthopedics (NASDAQ: MGRM) Lands Key Clinical Trial Partnership With India&#39;s Leading Orthopedic Hospital Group To Advance Its Surgical Robot Tech

xr:d:DAF1o5RCqe8:2,j:6153453808996259115,t:23113011

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMSC

BNAI

HLTH

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

NTNX

ONCO

ONMD

PATH

PSTG

SMFL

SNOA

STSS

VERB

Why Pure Storage Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Monogram Technologies Inc. - Common Stock

Monogram Technologies Inc

WIIM

CRGO

Freightos shares are trading lower after the company reported Q3 financial results and issued Q4 revenue guidance with its midpoint below estimates.

Rumble shares are trading higher after the company announced that Dr. Disrespect will provide exclusive content to Rumble Premium and lead Rumble Gaming as an advisor.

<p><strong>Cassava Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed<a href="https://www.benzinga.com/news/24/09/41007173/cassava-sciences-stock-rises-on-interim-safety-review-of-simufilam-phase-3-trials"> by the market</a>.</p>
<p><strong>Martin Shkreli</strong>, a well-know figure in the pharmaceutical space, predicted the stock&#8217;s crash Sunday night.</p>
<p><strong>What Happened</strong>: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, <a href="https://www.benzinga.com/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">sending shares significantly lower </a>to start the trading week.</p>
<p>The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety profile.</p>
<p>"Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease," the company said.</p>
<p>Cassava Sciences CEO <strong>Rick Barry </strong>called the results "disappointing for patients and their families."</p>
<p>Benzinga reached out to Cassava for comment.</p>
<p>Shkreli, a former hedge fund manager, predicted Monday's sharp shared decline.</p>
<p>"If you have $ on robinhood or interactive, short SAVA now," Shkreli <a href="https://x.com/MartinShkreli/status/1860886801617125798">tweeted </a>at 10:22 p.m. ET Sunday night.</p>
<p>The tweet signaled a belief that Cassava Sciences stock was set to fall.<strong> Robinhood </strong>and <strong>Interactive Brokers</strong> are among the brokers who offer 24-hour trading on select stocks, which is why they were named by Shkreli.</p>
<p>Shkreli was asked by several people on X if his tweet was financial advice, to which he replied yes. Shkreli also told people that waiting until Monday's opening bell at 9:30 a.m. ET would be too late to short the stock.</p>
<p>Cassava Sciences shares were halted at 7:25 a.m. ET with the company's update coming at 7:30 a.m. ET and shares resuming for trading at 7:55 a.m. ET.</p>
<p>Shares quickly fell Monday morning by over 80% after the company's update.</p>
<p>The post by Shkreli shouldn't come as a huge surprise since a Nov. 21 thread about a 38-page paper on Cassava by the former hedge fund manager is his pinned <a href="https://x.com/MartinShkreli/status/1859681514415607930">tweet</a>.</p>
<p>"I don't &#x2A;think&#x2A; it doesn't work. It is impossible for it to work," the thread says.</p>
<p>Shkreli said Alzheimer's Disease is a very tough market to target to begin with as 98% of the last Phase 3 trials for the disease have failed. Cassava's Phase 3 treating symptomatic patients could doom it, Shkreli predicted in the thread.</p>
<p>"Cassava bulls are looking for a ‘lotto ticket' return, but their chances are worse than the lotto."</p>
<p>Shkreli was extremely confident in his prediction, with a post <a href="https://x.com/MartinShkreli/status/1860878868028269051">listing </a>the things that he would do if the Phase 3 trial met its primary endpoint.</p>
<ol>
<li>Delete my X account</li>
<li>Shave my head on YouTube and delete that account as well</li>
<li>Begin estrogen therapy and legally change my name to Martina</li>
<li>Move to Haiti, bringing my best friend/cat Nibbles</li>
<li>Retire from business completely</li>
</ol>
<p>Shkreli took aim at WallSteetBets, a subreddit on Reddit Monday with a <a href="https://x.com/MartinShkreli/status/1861031460586831913">tweet </a>saying that "garbage like $SAVA" comes from the subreddit.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/options/24/11/41817544/looking-at-cassava-sciencess-recent-unusual-options-activity">Looking At Cassava Sciences&#8217;s Recent Unusual Options Activity</a></strong></p>
<p><strong>Why It's Important:</strong> Shkreli said Cassava not meeting the primary endpoint would make the stock "an easy short" and shares could trade near their cash value levels of $2 to $3 per share.</p>
<p>The prediction from Shkreli comes after the former hedge fund manager's wild past in the pharmaceutical sector. Known as "pharma bro" to many, Shkreli previously was CEO of <strong>Retrophin </strong>and <strong>Turing Pharmaceuticals.</strong> Shkreli <a href="https://www.benzinga.com/government/21/11/23904774/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro">famously raised the price</a> of antiparasitic drug Daraprim from $13.50 to $750 for insurance providers after Turing acquired the drug.</p>
<p>Shkreli was convicted of securities fraud in 2017 and currently has<a href="https://www.benzinga.com/news/24/10/41222384/pharma-bro-martin-shkreli-loses-appeal-supreme-court-imposes-65m-fine-issues-lifetime-ban-from-pharm"> a lifetime ban</a> from the pharmaceutical sector.</p>
<p><span style="box-sizing: border-box; margin: 0px; padding: 0px;">Before his recent Cassava Sciences focus, the former hedge funder has been making recent headlines in <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40185861/djt-trumpcoin-allegedly-launched-by-martin-shkreli-with-barron-trumps-help-tanks-98" target="_blank" rel="noopener">the cryptocurrency sector</a></span>.</p>
<p>Benzinga reached out to Shkreli for comment and did not hear back by the time of publication.</p>
<p><strong>Citron Research</strong>, known for their short reports, praised Shkreli's prediction on Cassava Sciences in a <a href="https://x.com/CitronResearch/status/1861043591369429143">tweet</a>.</p>
<p>"$SAVA illustrates the difficulty in shorting stocks. Has been a clear fraud for years but almost became an impossible short because of the ‘new market forces'. Nice to see some good homework by @martinshkreli added with a dose of reality to achieve real price discovery," Citron Research tweeted.</p>
<p><strong>SAVA Price Action: </strong>Cassava Sciences stock is down 84.6% to $4.06 on Monday versus a previous 52-week trading range of $8.79 to $42.20, hitting new 52-week lows.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre">SEC Charges Cassava Sciences Over Manipulated Alzheimer&#8217;s Trial Data, Company And Former Execs Agree To Pay Penalty</a></strong></li>
</ul>
<p><em>Photo: Wikimedia</em></p>


Health Care

SAVA

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

<p>Raymond James  analyst Brian MacArthur   maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and lowers the price target from $26 to $25.</p>


Price Target

Analyst Ratings

GOLD

Raymond James Maintains Outperform on Barrick Gold, Lowers Price Target to $25

<p>Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>), a premier multimodal provider of transportation, intermodal and logistics services, announced today the company, through certain wholly owned subsidiaries, has entered into a definitive agreement to acquire Cowan Systems, LLC and affiliated entities (collectively, "Cowan Systems"), for a cash purchase price of approximately $390 million, subject to certain adjustments. The sale includes separate agreements to purchase certain real estate assets relating to Cowan Systems' business for approximately $31 million in cash.</p>


SNDR

Schneider's Has Entered Into A Definitive Agreement To Acquire Cowan Systems And Affiliated Entities, For A Cash Purchase Price Of ~$390M

<p>Scotiabank  analyst Nicholas Yulico   maintains Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) with a Sector Outperform and raises the price target from $119 to $126.</p>


Scotiabank Maintains Sector Outperform on Federal Realty Investment, Raises Price Target to $126

<p>Scotiabank  analyst Greg McGinniss   maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a Sector Perform and raises the price target from $23 to $26.</p>


Scotiabank Maintains Sector Perform on Kimco Realty, Raises Price Target to $26

<p>Raymond James  analyst Brian MacArthur   maintains Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Outperform and lowers the price target from $62 to $59.</p>


Raymond James Maintains Outperform on Newmont, Lowers Price Target to $59

<p>United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect United Maritime to report an <strong>earnings per share</strong> (EPS) of $-0.05.</p>
<p>The announcement from United Maritime is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<p>Here's a look at United Maritime's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.09</td>
<td>-0.13</td>
<td>-0.07</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>United Maritime Share Price Analysis</h3>
<p>Shares of United Maritime were trading at $2.08 as of November 22. Over the last 52-week period, shares are down 13.33%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/USEA/earnings"><strong>To track all earnings releases for United Maritime visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

USEA

A Look Ahead: United Maritime's Earnings Forecast

<p>Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) will release its quarterly earnings report on Tuesday, 2024-11-26. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Icecure Medical to report an <strong>earnings per share</strong> (EPS) of $-0.07.</p>
<p>The market awaits Icecure Medical's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 0.98% drop in the share price on the following day.</p>
<p>Here's a look at Icecure Medical's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550465_0.png" alt="eps graph" /></p>
<h3>Market Performance of Icecure Medical's Stock</h3>
<p>Shares of Icecure Medical were trading at $0.7122 as of November 22. Over the last 52-week period, shares are down 39.48%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ICCM/earnings"><strong>To track all earnings releases for Icecure Medical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ICCM

What to Expect from Icecure Medical's Earnings

<p>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $47.75, a high estimate of $48.00, and a low estimate of $47.00. Marking an increase of 3.8%, the current average surpasses the previous average price target of $46.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550464_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Select Medical Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Select Medical Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Select Medical Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Select Medical Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SEM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Select Medical Hldgs analyst ratings.</strong></a></p>
<h2>Delving into Select Medical Hldgs's Background</h2>
<p>Select Medical Holdings Corp is a healthcare company that operates through four main segments: critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and Concentra institutions. Critical illness recovery hospitals and rehabilitation centres are designed for patients requiring extended recovery time with medical services. These two sectors combined compose roughly half of the total revenue and include over 103 critical illness recovery hospitals and inpatient rehab facilities. The outpatient rehabilitation segment includes over 1,928 rehabilitation clinics. The Concentra segment includes over 540 occupational health centers and 147 onsite clinics. The company is headquartered in Pennsylvania, and it operates across the United States.</p>
<h3>Breaking Down Select Medical Hldgs's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Select Medical Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>5.73%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Select Medical Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>3.04%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Select Medical Hldgs's ROE excels beyond industry benchmarks, reaching <strong>3.21%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.67%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Select Medical Hldgs's debt-to-equity ratio is below the industry average at <strong>2.39</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 4 Analyst Recommendations For Select Medical Hldgs

<p><strong>Ucloudlink Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ucloudlink Group will report an <strong>earnings per share</strong> (EPS) of $-0.01. </p>
<p>Ucloudlink Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 3.5% drop in the share price on the subsequent day.</p>
<p>Here's a look at Ucloudlink Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.01</td>
<td>-0.01</td>
<td>0.05</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.07</td>
<td>0.03</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-8.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550457_0.png" alt="eps graph" /></p>
<h3>Ucloudlink Group Share Price Analysis</h3>
<p>Shares of Ucloudlink Group were trading at $1.24 as of November 22. Over the last 52-week period, shares are down 41.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UCL/earnings"><strong>To track all earnings releases for Ucloudlink Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at Ucloudlink Group's Upcoming Earnings Report

<p>MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.09, a high estimate of $56.00, and a low estimate of $43.00. A 4.59% drop is evident in the current average compared to the previous average price target of $53.55. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550456_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of MGM Resorts Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Carlo Santarelli</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MGM Resorts Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MGM Resorts Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of MGM Resorts Intl's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MGM Resorts Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MGM Resorts Intl analyst ratings.</strong></a></p>
<h2>Delving into MGM Resorts Intl's Background</h2>
<p>MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 62% of total EBITDAR in 2023. MGM also owns US regional assets, which represented a low 20s share of 2023 EBITDAR (MGM's Macao EBITDAR was 17% of the total in 2023). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.</p>
<h3>MGM Resorts Intl's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, MGM Resorts Intl showcased positive performance, achieving a revenue growth rate of <strong>5.28%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> MGM Resorts Intl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.41%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MGM Resorts Intl's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.72%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MGM Resorts Intl's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.44%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>9.9</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


11 Analysts Assess MGM Resorts Intl: What You Need To Know

<p>Across the recent three months, 4 analysts have shared their insights on Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.75, a high estimate of $16.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 17.02% from the previous average price target of $11.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550448_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Sally Beauty Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sally Beauty Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sally Beauty Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Sally Beauty Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Sally Beauty Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SBH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sally Beauty Holdings analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Sally Beauty Holdings</h2>
<p>Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Colombia, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.</p>
<h3>Key Indicators: Sally Beauty Holdings's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Sally Beauty Holdings showcased positive performance, achieving a revenue growth rate of <strong>1.48%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Sally Beauty Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>5.14%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sally Beauty Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.97%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Sally Beauty Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.74%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Sally Beauty Holdings's debt-to-equity ratio surpasses industry norms, standing at <strong>2.54</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Sally Beauty Holdings Stands With Analysts

<p>MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect MediWound to report an <strong>earnings per share</strong> (EPS) of $-0.44.</p>
<p>The announcement from MediWound is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.24 in the last quarter, leading to a 4.01% increase in the share price on the following day.</p>
<p>Here's a look at MediWound's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.68</td>
<td>-0.39</td>
<td>-0.19</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550447_0.png" alt="eps graph" /></p>
<h3>Performance of MediWound Shares</h3>
<p>Shares of MediWound were trading at $16.48 as of November 22. Over the last 52-week period, shares are up 96.88%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MDWD/earnings"><strong>To track all earnings releases for MediWound visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MDWD

Earnings Preview: MediWound

<p><strong>American Woodmark</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-26. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that American Woodmark will report an <strong>earnings per share</strong> (EPS) of $2.37. </p>
<p>The market awaits American Woodmark's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.51, leading to a 0.99% drop in the share price on the subsequent day.</p>
<p>Here's a look at American Woodmark's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.40</td>
<td>1.78</td>
<td>1.29</td>
<td>2.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.89</td>
<td>1.70</td>
<td>1.66</td>
<td>2.36</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550437_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of American Woodmark were trading at $97.24 as of November 22. Over the last 52-week period, shares are up 42.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on American Woodmark</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on American Woodmark.</p>
<p>With 4 analyst ratings, American Woodmark has a consensus rating of Outperform. The average one-year price target is $111.0, indicating a potential 14.15% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Quanex Building Prods, Apogee Enterprises and Janus Intl Gr, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Quanex Building Prods is favoring an Buy trajectory, with an average 1-year price target of $38.0, suggesting a potential 60.92% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Apogee Enterprises, with an average 1-year price target of $75.0, implying a potential 22.87% downside.</li>
<li>The consensus among analysts is an Neutral trajectory for Janus Intl Gr, with an average 1-year price target of $10.4, indicating a potential 89.3% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary presents essential metrics for Quanex Building Prods, Apogee Enterprises and Janus Intl Gr, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Woodmark</td>
<td>Outperform</td>
<td>-7.85%</td>
<td>$92.87M</td>
<td>3.25%</td>
</tr>
<tr>
<td>Quanex Building Prods</td>
<td>Buy</td>
<td>-6.44%</td>
<td>$70.90M</td>
<td>4.37%</td>
</tr>
<tr>
<td>Apogee Enterprises</td>
<td>Neutral</td>
<td>-3.18%</td>
<td>$97.32M</td>
<td>6.20%</td>
</tr>
<tr>
<td>Janus Intl Gr</td>
<td>Neutral</td>
<td>-17.85%</td>
<td>$91.20M</td>
<td>2.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>American Woodmark ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks in the middle for Return on Equity.</p>
<h3>Unveiling the Story Behind American Woodmark</h3>
<p>American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.</p>
<h3>Key Indicators: American Woodmark's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> American Woodmark's revenue growth over a period of 3 months has faced challenges. As of 31 July, 2024, the company experienced a revenue decline of approximately <strong>-7.85%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> American Woodmark's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.45%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> American Woodmark's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.25%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.84%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.57</strong>, American Woodmark adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/AMWD/earnings"><strong>To track all earnings releases for American Woodmark visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AMWD

What's Next: American Woodmark's Earnings Preview

<p>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for TG Therapeutics, presenting an average target of $43.8, a high estimate of $55.00, and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 18.38% from the previous average price target of $37.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550437_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of TG Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tara Bancroft</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TG Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of TG Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of TG Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into TG Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TGTX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TG Therapeutics analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind TG Therapeutics</h2>
<p>TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.</p>
<h3>Financial Insights: TG Therapeutics</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> TG Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-49.41%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> TG Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>4.63%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> TG Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.1%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> TG Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.79%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.32</strong>, TG Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TGTX

TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Deep-pocketed investors have adopted a bearish approach towards GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GME usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for GameStop. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 23% leaning bullish and 46% bearish. Among these notable options, 5 are puts, totaling $151,072, and 8 are calls, amounting to $374,860.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $125.0 for GameStop during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for GameStop's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across GameStop's significant trades, within a strike price range of $15.0 to $125.0, over the past month.</p>
<h3>GameStop Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550432_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GME</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.65</td>
<td>$5.6</td>
<td>$5.65</td>
<td>$25.00</td>
<td>$93.2K</td>
<td>7.5K</td>
<td>1.9K</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$3.7</td>
<td>$3.55</td>
<td>$3.7</td>
<td>$25.00</td>
<td>$74.0K</td>
<td>5.6K</td>
<td>749</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$3.5</td>
<td>$1.69</td>
<td>$1.9</td>
<td>$36.00</td>
<td>$49.4K</td>
<td>149</td>
<td>260</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$1.12</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$30.00</td>
<td>$35.5K</td>
<td>25.6K</td>
<td>13.7K</td>
</tr>
<tr>
<td>GME</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$3.7</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$28.00</td>
<td>$35.5K</td>
<td>1.0K</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About GameStop</h3>
<p>GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. GameStop sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States.</p>
<p>Following our analysis of the options activities associated with GameStop, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is GameStop Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,029,729, the GME's price is up by 3.19%, now at $28.79. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for GameStop, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

GameStop's Options Frenzy: What You Need to Know

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Palo Alto Networks</strong>.</p>
<p>Looking at options history for Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) we detected 22 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 45% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $182,515 and 20, calls, for a total amount of $1,144,970.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $420.0 for Palo Alto Networks during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Palo Alto Networks's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palo Alto Networks's whale trades within a strike price range from $250.0 to $420.0 in the last 30 days. </p>
<h3>Palo Alto Networks 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550427_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$141.5</td>
<td>$135.55</td>
<td>$141.5</td>
<td>$250.00</td>
<td>$141.5K</td>
<td>46</td>
<td align="right">0</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$8.0</td>
<td>$7.6</td>
<td>$8.0</td>
<td>$395.00</td>
<td>$129.6K</td>
<td>172</td>
<td align="right">182</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$35.4</td>
<td>$34.05</td>
<td>$34.0</td>
<td>$390.00</td>
<td>$122.4K</td>
<td>231</td>
<td align="right">36</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$27.5</td>
<td>$26.6</td>
<td>$27.5</td>
<td>$370.00</td>
<td>$82.5K</td>
<td>1.2K</td>
<td align="right">38</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$8.0</td>
<td>$6.6</td>
<td>$8.0</td>
<td>$387.50</td>
<td>$80.0K</td>
<td>147</td>
<td align="right">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palo Alto Networks</h3>
<p>Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.</p>
<p>In light of the recent options history for Palo Alto Networks, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Palo Alto Networks Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,319,843, the PANW's price is up by 1.4%, now at $388.73. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 85 days.</li>
</ul>
<h3>Expert Opinions on Palo Alto Networks</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $409.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Palo Alto Networks, maintaining a target price of $385.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Palo Alto Networks, targeting a price of $420.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Palo Alto Networks, maintaining a target price of $449.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Palo Alto Networks, maintaining a target price of $425.<br />
&#x2A; Reflecting concerns, an analyst from Northland Capital Markets lowers its rating to Market Perform with a new price target of $370.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palo Alto Networks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PANW

This Is What Whales Are Betting On Palo Alto Networks

<p>In the latest quarter, 19 analysts provided ratings for Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.74, a high estimate of $75.00, and a low estimate of $25.00. This current average reflects an increase of 21.64% from the previous average price target of $44.18. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732550424_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Affirm Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Vincent Caintic</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Positive</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Underperform</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Affirm Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Affirm Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Affirm Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Affirm Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AFRM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Affirm Holdings analyst ratings.</strong></a></p>
<h2>Discovering Affirm Holdings: A Closer Look</h2>
<p>Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.</p>
<h3>Affirm Holdings's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Affirm Holdings's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>40.67%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-14.35%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-3.6%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Affirm Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.02%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Affirm Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.51</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AFRM

Assessing Affirm Holdings: Insights From 19 Financial Analysts

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Monogram Technologies</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mgrm-stock-quote/"><strong>MGRM</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Monogram Technologies reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -9 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/mgrm-stock-earnings-monogram-technologies-for-q2-of-2024/">MGRM Stock Earnings: Monogram Technologies Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

MGRM Stock Earnings: Monogram Technologies Misses EPS for Q2 2024

Monogram Orthopaedics Inc ( ($MGRM) ) has provided an update. Monogram Technologies Inc. has increased its continuous offering of units, which incl...

Monogram Orthopaedics Expands Offering for Corporate Growth

Monogram Orthopaedics Inc ( ($MGRM) ) just unveiled an update. Monogram Technologies Inc. has announced a quarterly dividend of $0.0255 per share f...

Monogram Orthopaedics Announces Quarterly Preferred Dividend

Monogram Orthopaedics Inc ( ($MGRM) ) has issued an announcement. Monogram Technologies Inc. successfully closed its Series D Preferred Stock offer...

Monogram Orthopaedics Secures Funding and Pursues FDA Approval

Monogram Orthopaedics Inc ( ($MGRM) ) has issued an announcement. Monogram Technologies Inc. has issued a correction to a previous announcement, sp...

Monogram Orthopaedics Clarifies FDA Response Timeline

Warning: MGRM is at high risk of performing badly

An update from Monogram Orthopaedics Inc ( ($MGRM) ) is now available. Monogram Technologies Inc., a leading AI-driven robotics company, has been r...

Monogram Orthopaedics Wins 2024 Orthopedic Company Award

Monogram Technologies Inc. GAAP EPS of -$0.16 misses by $0.05

Monogram Technologies Inc. (MGRM) Q3 2024 Earnings Call Transcript

Screenshot 2024-05-22 at 5.35.52 PM

Technology Is Enabling Remote Work In More And More Fields – Could Surgery Be Next? Surgical Robot Maker Monogram Orthopedics (NASDAQ: MGRM) Believes So

Screenshot 2024-05-02 at 5.54.18 PM

Emerging Markets

AI In Orthopedic Surgery: How Leveraging AI Could Improve Surgical Outcomes

Screenshot 2024-03-18 at 5.30.26 PM

Movers & Shakers

Monogram Orthopaedics (NASDAQ: MGRM) Aims To Overcome Robot Shortcomings With Its Advanced Solution

Press Releases

Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million

Dividends

Monogram Technologies Announces Preferred Stock Dividends

Legal

Monogram Technologies Receives FDA Response for mBôs TKA System

Offerings

Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering

CORRECTION FROM SOURCE: Monogram Technologies Issues Correction to Press Release Announcing it Received an FDA Response for its mBôs TKA System

Events

Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024

Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

Monogram Technologies Reports Third Quarter 2024 Financial Results

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Monogram Technologies

Monogram Technologies (MGRM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga